HEPACAM1 and 2 are differentially regulated in canine mammary adenomas and carcinomas and its lymph node metastases by Klopfleisch, Robert et al.
RESEARCH ARTICLE Open Access
HEPACAM1 and 2 are differentially regulated in
canine mammary adenomas and carcinomas and
its lymph node metastases
Robert Klopfleisch
1*, Patricia Klose
1, Afonso da Costa
1, Leo Brunnberg
2, Achim D Gruber
1
Abstract
Background: Cell adhesion is an important regulator of cell growth and motility. Recently the hepatocyte cell
adhesion molecules 1 and 2 (HEPACAM1 and 2), members of the immunoglobulin family of adhesion genes, have
been identified. HEPACAM1 is involved in negative cell cycle regulation via p53, p21 and p27 signalling but also
mediates increased human breast cancer cell spread. The role and expression pattern of HEPACAM2 has not been
analyzed so far. In the present study we quantified gene expression levels of HEPACAM1 and 2 to evaluate their
possible role during the carcinogenesis of canine mammary tumours.
Results: Adenomas displayed increased HEPACAM1 and 2 mRNA expression levels and decreased HEPACAM1
protein expression levels when compared to normal gland, carcinomas and lymph node metastases. In contrast,
metastatic carcinomas, intravascular tumour cells and lymph node metastases had HEPACAM 1 protein and mRNA
expression levels similar to normal gland but decreased HEPACAM2 mRNA expression when compared to normal
gland of the same dog.
Conclusions: HEPACAM1 and 2 seem to be important for cell-cell adhesion of normal and neoplastic canine
mammary cells. The loss of HEPACAM1 protein expression in adenomas but not in carcinomas questions its role as
a tumour suppressor at late stages of malignant transformation and indicates that it might rather be involved in
physiologic mammary cell adhesion and canine mammary tumour metastasis. Furthermore, it can be speculated,
whether HEPACAM2 plays a different role in malignancy and metastasis of canine mammary tumours since its
transcriptional levels are different in carcinomas and their lymph node metastases when compared to HEPACAM1.
Background
Cell adhesion to neighbouring cells and the extracellular
matrix is a dynamic process and essential for the main-
tenance of the cellular differentiation status. In contrast,
metastatic progression of epithelial tumours is regularly
associated with loss of cell-cell contact and a decrease
in cell differentiation. The same is obviously true for
canine mammary tumours that regularly show meta-
static spread to distant organs including the lung. It is
therefore not surprising that invasive character and
metastatic spread of canine mammary tumours (CMT)
is associated with decreased expression of cell adhesion
associated genes like E-Cadherin, Connexin 26, 43 and
Paxillin [1-3]. However, these genes not only act as a
cellular anchor but also strongly influence cellular pro-
liferation and migratory status through complex down-
stream signalling cascades [4,5].
Recently we found a significant decrease in expression
levels of the cell cycle inhibitor p27 in metastatic canine
mammary carcinomas and their lymph node metastases
[6,7]. So far, decreased expression of transforming
growth factor b (TGFb) family members has been iden-
tified as a possible cause of decreased p27 expression
levels and increased cellular proliferation of canine
mammary tumours [8]. However, due to the ambivalent
anti-proliferative and growth stimulatory roles of TGFb
at different stages of mammary tumour carcinogenesis
other upstream regulators may be involved in the
release of cell cycle brakes like p27 [9]. The hepatocyte
cell adhesion molecule 1 (HEPACM1) has been identi-
fied as a link between cell cycle arrest at the G2/M
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a breast cancer cell line [10]. However, HEPACAM1
also modulates cell-extracellular matrix interaction and
supports breast cancer cell spread [11]. On the tran-
scriptional level HEPACAM1 expression is decreased in
several human cancer types including breast cancer but
protein expression was not analyzed so far [10]. The
role of the HEPACAM family member 2 (HEPACAM2)
in normal and neoplastic mammary epithelial cells is
unknown.
Due to the findings in human tissues we hypothesized
that HEPACAM1 expression might be involved in the
decreased p27 expression levels in canine mammary
tumours. In the present study we therefore characterized
the differential mRNA expression of HEPACAM1 and 2
in laser microdissected frozen tissue samples and HEPA-
CAM1 protein expression in normal mammary gland
epithelium, adenomas and metastatic canine mammary
carcinomas, intravascular tumour cells and lymph node
metastases.
Results
mRNA and protein expression levels of HEPACAM1 in
normal gland, primary tumours, intravascular tumour
cells and lymph node metastases
HEPACAM1 mRNA expression was significantly increased
in adenomas when compared to normal gland, carcinomas
and lymph node metastases (Table 1, Figure 1).
Table 1 mRNA and protein expression levels of HEPACAM1 and 2 in tissue samples of non-neoplastic canine
mammary gland and canine mammary tumours
Gene Normal gland Adenoma Carcinoma IVTC Lymph node metastases
Average fold change in mRNA expression levels relative to normal gland of the same dog
HEPACAM1* 1 5.2 (SD ± 2.4) 1.9 (SD ± 1.2) - 1.5 (SD ± 1.2)
HEPACAM2* 1 4.0 (SD ± 2.0) 0.1 (SD ± 0.4) - 0.1 (SD ± 0.3)
Percentage of immunohistochemical HEPACAM positive tissue samples
HEPACAM1 100% 13% 94% 95% 89%
IVTC: Intravascular tumour cells
* Significant differences (p < 0.05) in mRNA expression levels were observed between microdissected adenomas/carcinomas and adenomas/lymph node
metastases (ANOVA)
Figure 1 Comparison of average fold change in HEPACAM1 and HEPACAM2 mRNA expression in canine mammary adenomas,
carcinomas and lymph node metastases (IVTC = Intravascular tumour cells).
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sion levels higher than 2.0 fold of the normal gland of the
same dog. In contrast, HEPACAM1 mRNA expression
was not significantly changed in carcinomas and their
lymph node metastases when compared to normal gland
(Table 1, Figure 1).
HEPACAM1 protein was expressed at the cell mem-
branes of all normal gland specimens (Table 1, Figure
2A). Furthermore, 94% of carcinomas, 95% of intra-
vascular tumour cells and 89% lymph node metastases
had HEPACAM1 protein expression in more than
10% of cells (Figure 2B, C, D). Surprisingly, only 13
percent of adenomas had membrane-bound HEPA-
CAM1 protein expression (Table 1, Figure 2A),
despite their increased HEPACAM1 transcription
levels.
mRNA expression levels of HEPACAM2 in normal gland,
primary tumours and metastases
HEPACAM2 mRNA expression was significantly
increased in microdissected adenomas when compared to
normal gland, carcinomas and lymph node metastases
(Table 1, Figure 1). In detail, seven out of ten adenomas
had mRNA expression levels higher than 2.0 fold of the
normal gland HEPACAM2 expression of the same dog.
In contrast, 12 out of 13 carcinomas and 13 out of 13
lymph node metastases had decreased HEPACAM2
mRNA expression levels lower than 0.5 fold of the nor-
mal gland epithelium of the same dog (Table 1, Figure 1).
Discussion
The exact mechanisms of canine mammary tumour
metastasis are unknown and this is one reason that
Figure 2 Mammary gland, dog. Immunohistochemical detection of HEPACAM1 protein. (A) Non neoplastic mammary gland with
membrane-bound expression of HEPACAM1 (right) and adenoma with complete loss of HEPACAM1 expression (left). Bar = 1250 μm. (B) In
contrast, almost all carcinomas expressed membrane-bound HEPACAM1. Bar = 250 μm (C) Intravascular tumour cells expressed HEPACAM1 at
their cell membrane. Bar = 200 μm (D) The majority of tumour cells lymph node metastases of mammary carcinomas expressed membrane
bound HEPACAM1 with increased expression at sites of cell to cell contact. Bar = 300 μm Haematoxylin counterstain.
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this tumour type except excision of the primary tumour.
In the present study we therefore asked whether HEPA-
CAM1 is a potential tumour suppressor in canine mam-
mary gland and whether its expression is decreased
similar to human breast cancer. Furthermore, we aimed
at identifying the HEPACAM2 expression levels at dif-
ferent stages of malignant progression of canine mam-
mary gland epithelium.
Normal mammary gland, carcinomas and metastatic
cells constantly expressed membrane-bound HEPA-
CAM1. In contrast, almost none of the adenomas
expressed HEPACAM1 protein despite increased HEPA-
CAM1 mRNA expression levels. These surprising find-
ings raise several questions regarding potential roles of
HEPACAM1 during malignant transformation of canine
mammary tumours. Assuming that the HEPACAM1
protein expressed in carcinomas is functionally active,
the role of HEPACAM1 as a tumour suppressor via
p21, p27 and p53 in canine mammary tumours is ques-
tionable. On the contrary, it can be hypothesized that
HEPACAM1 expression is associated with increased
metastatic spread and cell motility as has been shown
for human breast cancer cells before [12]. It will be
interesting to analyze in an additional study whether
non-metastatic carcinomas differ from metastatic carci-
nomas by decreased expression levels of HEPACAM1
protein. However, HEPACAM 1 obviously has also a
physiologic role in normal mammary gland cell adhesion
and maybe in cell cycle control since virtually all normal
gland epithelial cells express the protein.
The differences in HEPACAM1 mRNA and protein
expression levels in adenomas when compared to carci-
nomas indicate that decreased HEPACAM1 protein
levels in adenomas is caused by failure of mRNA trans-
lation or increased proteolysis. However, decreased pro-
tein expression levels may induce increased
H E P A C A M 1t r a n s c r i p t i o ni na d e n o m a si naf e e d b a c k
mechanism, although other so far unknown transcrip-
tion inducers may also cause the increased mRNA
expression levels.
The function and expression pattern of the expected
immunoglobulin-like, membrane protein HEPACAM2
has not been analyzed in any species so far. In the pre-
sent study, we found an increased HEPACAM2 expres-
sion in adenomas when compared to normal gland. In
contrast, carcinomas and lymph node metastases had a
constant and marked decrease in HEPACAM2 expres-
sion levels. HEPACAM1 and 2 mRNA expression levels
are therefore similar in adenomas, while carcinomas and
metastases have decreased HEPACAM2 but not HEPA-
CAM1 mRNA expression levels. It can therefore be
speculated that HEPACAM2 expression decreases with
increasing malignancy of canine mammary tumours as
is usually observed for cell-adhesion genes in a wide
variety of tumours types. However, evaluation of the
protein expression pattern is needed to support the
findings for HEPACAM2 on the transcriptional level.
Unfortunately, HEPACAM2 specific antibodies are not
available so far for any species.
Conclusions
A significant decrease in HEPACAM1 protein expres-
sion was found in canine mammary adenomas. In con-
trast, HEPACAM1 protein was constantly expressed in
normal mammary gland, carcinomas, intravascular
tumour cells and metastatic cells. The data question the
role of HEPACAM1 as an effective tumour suppressor
at late stages of canine mammary carcinogenesis. In
contrast, the HEPACAM1 expression pattern makes it
more likely that the protein is involved in physiologic
cell adhesion of the canine mammary epithelium and
also in metastatic spread of canine mammary tumours.
HEPACAM2 transcription levels were decreased in
mammary carcinomas but further analysis of the func-
tion and the expression pattern of the HEPACAM2 pro-
tein are needed to evaluate its role in normal mammary
gland physiology and malignant transformation.
Methods
Dogs and tissue processing
Thirty simple, tubulopapillary and solid carcinomas with
metastases in the regional lymph node, thirty simple
adenomas and the normal mammary gland of the same
dogs but from a different mammary complex were
included in the study. For 13 simple, tubulopapillary
and solid carcinomas, 13 lymph node metastases of the
same dogs, 10 simple adenomas and the 23 normal
glands of all dogs, fresh frozen tissue specimens were
available from intact female dogs in anestrus and proes-
trus and used for laser microdissection and mRNA iso-
lation. These tissues were snap frozen in liquid nitrogen
at -80°C within 15 min after resection and stored until
further use. Paraffin sections (2 μm) of all tissues were
routinely stained with hematoxylin and eosin and
tumours were classified according to the World Health
Organization (WHO) [13]. The study was approved by
the local animal welfare officer and informed consent
was obtained from patient owners. No additional harm
was caused by the study and tissue samples were surgi-
cally removed based solely to improve the animal health.
Laser-capture microdissection and reverse transcription
To obtain highly specific microdissected tumour cell
samples without contamination by other cells types, five
consecutive sections of 6-8 μmt h i c k n e s sf r o mt h e
frozen tissue samples were mounted on glass slides
covered with a polyethylene naphthalate membrane
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2 min in 95% ethanol at -20°C and stained with hematox-
ylin and eosin in diethylpyrocarbonate (DEPC)-treated
water. Sections were then dehydrated in ascending
graded ethanol (30, 50, 70, 99%). Approximately, 5 × 10
6
μm
2 were excised from tissue sections of normal mam-
mary gland, adenomas, carcinomas and lymph node
metastases. Cells were laser pressure catapulted into the
caps of 0.5-ml reaction tubes containing 20 μLo fl y s i s
buffer (NucleoSpin RNA XS;M a c h e r e y & N a g e l ) .T o t a l
RNA was extracted and purified using a commercial kit
(NucleoSpin RNA XS; Macherey&Nagel) including
DNAse digestion. Total RNA was reverse transcribed
using the iScript cDNA synthesis kit (Biorad).
Quantitative real-time polymerase chain reaction
(qRT-PCR)
Primer sequences for HEPACAM1, HEPACAM2 and
the housekeeping genes hypoxanthine-phosphoribosyl
transferase (HPRT), ATP-synthase subunit 5B (A5B),
ribosomal protein L32 (RPL32) are shown in Table 2.
Real-time qRT-PCR and data analyses were performed
using the MX 3000P Quantitative PCR System and MX
Pro software (Stratagene) as recently described [14]. The
reactions were carried out in 96-well polypropylene
plates covered with optical caps (Stratagene). The plates
contained triplicates of each cDNA sample and no-
template controls with water instead of cDNA templates.
PCR products were sequenced to evaluate specificity of
the primer pairs. The 15-μL reaction mix contained 5 μL
cDNA, 12.5 μL Brilliant SYBR Green QPCR Master Mix
(Fermentas) with 300 nM of each primer. Cycling condi-
tions were 10 min at 95°C, followed by 40 cycles of 30 s
at 95°C, 1 min at 58°C, and 30 s at 72°C. The cDNA of all
samples were amplified on the same plate for every pri-
mer pair to ensure equal amplification conditions. Speci-
ficity of amplification products was confirmed by melting
curve analyses. For each sample, results were documen-
ted as cycle threshold (threshold set to 100 relative fluor-
escence units) values of background subtracted qPCR
fluorescence kinetics by using the MX Pro Stratagene
analysis software, applying the adaptive baseline, amplifi-
cation based threshold, and moving average algorithm
enhancement.
Quantification of target gene expression
mRNA expression levels of the target genes (TG) were
quantified using the ΔΔCT-method with multiple
housekeepers as previously described [15,16]. House-
keeper genes were selected from a panel of reference
genes (RG) according to the GeNorm algorithm and
represent the best reference genes for canine mammary
gland. Fold change (FC) in TG expression levels in the
sample of interest (SOI) was normalized to geometric
mean of housekeeper gene expression and relative to
the normal mammary gland epithelium (NG). Finally
the FC of GOI expression was calculated with the
ΔCTGOI multiplied by the normalization factor. Specifi-
cally, gene expression levels of all adenomas, carcinomas
and lymph node metastases (SOI) was normalized to
RG expression and compared to NG of the same dog.
Normal distribution and significance of differences in
mRNA expression levels in the different tissues were
confirmed by Kolgomorow-Smirnow-Test and univariate
ANOVA.
Immunohistochemistry
HEPACAM1 expression was immunohistochemically
detected using the ABC-method. HEPACAM1 specific
antibody (pab, 1:150; Sigma, HPA017613) was diluted in
Tris-buffered saline (TBS, 50 mM, pH 7.6) and incu-
bated at 4°C overnight after a blocking step with 50%
goat serum in TBS (30 min at room temperature).
Detection of HEPACAM1 required antigen retrieval by
citrate pre-treatment for 30 min at 96°C. Goat anti-rab-
bit IgG (pab, 1 in 200; Vector, BA1000) was used as sec-
ondary antibody. Diaminobenzidine tetrahydrochloride
(Sigma Aldrich) was used as chromogen and slides were
counterstained with hematoxylin. As positive control
paraffin embedded human liver specimen was used. As
negative control, sections were incubated with an unspe-
cific immune serum. No unspecific staining was
Table 2 Primer Sequences of used for qPCR
Gene Primer sequence (5’ -3 ’) Amplicon size Accession no.
HEPACAM1 fw-CACTGGAGAGAAGACCATCAA
rev- CTCGTGGGAGCAGTTGAG
120 bp ENSCAFT00017511
HEPACAM2 fw-GCTCCAGTGACCAAAGAAGA
rev- CTCGAAGTCCATAAGGTCCA
117 bp ENSCAFT0003183
HPRT fw-TGCTCGAGATGTGATGAAGG
rev-TCCCCTGTTGACTGGTCATT
191 bp NM_000194
A5B fw-GCACGGAAAATACAGCGTTT
rev-TTGCCACAGCTTCTTCAATG
186 bp NM_001686
RP32 fw-ATGCCCAACATTGGTTATGG
rev-CTCTTTCCACGATGGCTTTG
180 bp XM_540107
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in 10 random 400× magnification fields in three serial
sections and graded negative if less than 10% of the cells
in a tumour were immunohistochemically positive.
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